Data status: August 23, 2026. Eli Lilly’s Q2 2026 results look less like a normal pharmaceutical quarter and more like the emergence of a metabolic platform. Revenue increased 48% to $22.97 billion. Mounjaro generated $9.94 billion, up 91%, while Zepbound reached $4.93 billion, up 46%. Together, the two tirzepatide products produced almost $15 billion in one quarter.
The obvious bull case for Eli Lilly stock is that obesity and metabolic disease remain massively underpenetrated. The harder question is valuation. A company can execute exceptionally and still disappoint shareholders if the market has already capitalized too much future success into the share price.
Q2 2026 in numbers
- Revenue: $22.97 billion, up 48%.
- Reported EPS: $7.94.
- Non-GAAP EPS: $8.38.
- Gross margin: $19.7 billion, or 85.8% of revenue.
- Mounjaro revenue: $9.94 billion.
- Zepbound revenue: $4.93 billion.
- 2026 revenue guidance: $85 billion to $87 billion.
- R&D expense: about $3.8 billion.
Tirzepatide is becoming a franchise
Mounjaro and Zepbound use the same active molecule but operate across different indications and reimbursement frameworks. That allows Lilly to monetize one scientific platform across diabetes, obesity and potentially additional metabolic conditions.
The economic benefit is not limited to revenue. Manufacturing know-how, physician familiarity, safety data and commercial infrastructure can be shared. Each additional indication can improve the return on the original scientific and manufacturing investment.
Obesity is not a normal drug market
The eligible population is enormous, treatment penetration remains low, and demand is constrained by coverage, supply, affordability and willingness to remain on therapy. That creates a very wide range of possible market sizes.
The same drug can produce very different revenue depending on how many patients receive coverage, how long they stay on treatment and what net price payers negotiate. For Lilly, reimbursement is therefore almost as important as clinical efficacy.
Volume is rising faster than realized price
Lilly’s worldwide revenue growth was driven heavily by volume while realized pricing declined. This is a crucial detail. Lower net prices can expand access and bring more patients into treatment, but they also mean prescriptions can grow faster than revenue.
The best long-term outcome is not necessarily the highest possible list price. It may be a sustainable price low enough to unlock broad reimbursement while still generating excellent returns on manufacturing and R&D.
Manufacturing is part of the moat
Investors often focus on molecules and patents while underestimating the challenge of making enough product. Lilly has committed billions of dollars to manufacturing expansion. Capacity can become a competitive advantage when demand is larger than available supply.
A physician can prefer a therapy and still avoid prescribing it if pharmacies cannot reliably obtain it. A payer can negotiate coverage and still frustrate patients if shortages persist. Supply consistency is therefore part of the commercial product.
Retatrutide gives Lilly a next-generation option
Retatrutide is strategically important because a strong pharmaceutical franchise often has to replace itself before competitors do. A next-generation therapy can segment patients, protect market share and extend the economic life of the metabolic platform.
If retatrutide ultimately offers compelling efficacy and acceptable safety, Lilly can cannibalize part of tirzepatide itself rather than waiting for a rival to do it. That is the kind of internal disruption I want from a premium pharmaceutical company.
Oral obesity can expand the market
Oral therapies can reach patients unwilling to use injections and may be easier to distribute across health systems. They may also face stronger price competition. I therefore view oral obesity as market expansion rather than assume it carries the same economics as leading injectable products.
Convenience can matter nearly as much as efficacy in real-world adoption. Dosing, gastrointestinal tolerability, storage, insurance and patient preference all affect persistence.
Duration of treatment is a hidden revenue driver
If patients remain on therapy for years, lifetime revenue per patient is dramatically higher than if discontinuation occurs after a few months. Real-world persistence can differ from clinical trials because cost, side effects and expectations influence behavior.
For that reason, I would monitor adherence and persistence data as closely as new prescriptions. The size of the market depends on how many patients remain treated, not merely how many start.
The pipeline must broaden beyond obesity
Lilly is also investing in immunology, oncology and neuroscience. Those programs matter because patent cliffs eventually arrive. A premium pharmaceutical multiple is justified only if the R&D engine can create new franchises before existing ones lose exclusivity.
The market is therefore underwriting more than Mounjaro and Zepbound. It is underwriting Lilly’s ability to repeatedly move programs from clinical development to approval and then scale them commercially.
R&D spending is valuable only when it is productive
Lilly spent roughly $3.8 billion on R&D in the quarter. In pharmaceuticals, that expense is the raw material for future revenue. But a large pipeline can also hide many failed projects.
I therefore track progression through clinical stages rather than counting the number of assets on a slide. Movement from Phase 2 to Phase 3 to approval is more informative than pipeline breadth by itself.
Acquisitions create optionality and capital-allocation risk
Abundant obesity cash flow gives Lilly the ability to acquire external science. That is useful because no internal R&D organization has a monopoly on good ideas. It is also dangerous because successful companies can overpay when capital feels plentiful.
I want management to use its financial strength aggressively but with evidence of discipline. Buying a promising molecule is not the same as creating value from it.
Gross margin is exceptional, but it is not the moat
A gross margin above 85% demonstrates the economics of successful branded pharmaceuticals. But high margins can disappear after patent expiry, competitive entry or reimbursement pressure. The true moat is the combination of intellectual property, clinical differentiation, physician adoption, manufacturing scale and pipeline renewal.
A single blockbuster can look extraordinarily profitable while still containing a countdown clock. Lilly deserves a premium only if it keeps resetting that clock with new products.
Competition with Novo Nordisk is not winner-take-all
The obesity market is large enough for multiple therapies and patient segments. Competition will occur on efficacy, side effects, dosing, supply, payer access and net price.
Even a market dominated by two major companies can be competitive. Payers can use alternatives against each other when negotiating preferred formulary status. Concentration therefore does not automatically guarantee pricing power.
International economics will differ from the U.S.
Pricing and reimbursement vary dramatically by country. Lower international prices can still produce attractive economics if volume is large and manufacturing scale is efficient. I would not extrapolate U.S. revenue per patient to the rest of the world.
Valuation framework
| Scenario | 2030 revenue | Normalized net margin | Core assumption |
|---|---|---|---|
| Bear | $120bn | 28% | Pricing pressure offsets much of the volume growth. |
| Base | $155bn | 32% | Tirzepatide expands globally and pipeline contributes. |
| Bull | $190bn | 34% | Next-generation and oral obesity extend leadership. |
The difficult part is that even the bear case describes a much larger company. That is the danger of premium growth valuations. Operational success may not be enough if expectations were even higher.
What I would watch next
- Mounjaro and Zepbound revenue growth.
- Net realized price versus volume growth.
- Manufacturing capacity and shortage status.
- International reimbursement wins.
- Retatrutide regulatory progress.
- Oral-obesity adoption.
- Pipeline progression outside metabolic disease.
- Acquisition spending.
- Free-cash-flow conversion.
What would make me more bullish?
Broader payer coverage, strong international volume, successful next-generation filings and evidence that pipeline assets outside obesity are creating meaningful new franchises would strengthen the thesis. I would also become more constructive if net pricing stabilizes while volume remains strong.
What would break the thesis?
The thesis weakens if net pricing falls faster than patient volume grows, if manufacturing cannot support demand, or if competing therapies materially reduce Lilly’s share. A second warning would be large acquisition spending without corresponding pipeline productivity.
My conclusion
Lilly is no longer merely selling two blockbuster drugs. It is building a metabolic franchise with manufacturing scale, multiple formulations and next-generation molecules. Q2 confirmed the strength of that platform with 48% revenue growth and nearly $15 billion of combined Mounjaro and Zepbound revenue.
The company quality is easier to defend than the valuation. I would prefer to buy during periods when policy fears, trial uncertainty or broad market weakness create a gap between the long-term franchise and the short-term narrative.
The core thesis is simple: obesity treatment is a structural healthcare market, and Lilly currently has one of the strongest positions in it. The investment return depends on how much of that future investors have already paid for.
Primary sources
This article is analysis, not investment advice. Scenario figures are illustrative.
The real obesity-market debate is duration
The addressable population is enormous, but the value of each patient depends on how long treatment continues. A therapy used for years produces very different economics from one discontinued after several months. Real-world persistence therefore matters almost as much as prescription growth.
Manufacturing returns deserve the same attention as clinical data
Lilly is investing heavily in capacity. That spending can create a moat when supply is scarce, but overcapacity would lower returns if demand growth slows or competitors expand faster than expected.
The right question is not simply whether capacity increases. It is whether utilization remains high while net pricing stays attractive.
Pipeline diversification protects against concentration
Tirzepatide is becoming so large that the company increasingly needs successful products outside metabolic disease to preserve long-term quality. Neuroscience, oncology and immunology programs are important not because they must match obesity revenue, but because they reduce dependence on one franchise.
Why valuation should use a probability-weighted pipeline
Drug pipelines are uncertain. A Phase 3 asset should carry more value than a Phase 1 program, but neither should be valued as if approval were guaranteed. A probability-weighted approach is more realistic than assigning full commercial value to every promising molecule.
This is consistent with the framework I use in Aktienanalyse mit KI: separate current cash-generating assets from future optionality and apply different confidence levels to each.
Related reading on The Kapital
For a broader discussion of valuation risk in high-growth companies, see our growth-stock valuation guide.
FAQ
Is obesity demand already fully penetrated?
No. Penetration remains low relative to the potential patient population, but reimbursement, affordability and persistence will determine the size of the realized market.
What is the biggest risk to Lilly?
Pricing pressure, competitive therapies and disappointing next-generation pipeline results are the main structural risks.
Why is manufacturing a moat?
Reliable supply matters when demand exceeds capacity. A clinically strong drug that cannot be consistently supplied loses commercial momentum.
What would justify a premium valuation?
Sustained tirzepatide growth, successful next-generation products and evidence that Lilly can create meaningful franchises outside metabolic disease.
Pricing pressure does not automatically destroy the thesis
Lower net pricing can expand the treated population. A lower price per patient may still create more total profit if access improves materially and manufacturing scale reduces cost per dose.
The relevant question is therefore elasticity: how much additional volume does Lilly gain for each reduction in net price?
Why cardiovascular and metabolic outcomes matter
Obesity drugs become more valuable to payers when they demonstrate benefits beyond weight loss. Reductions in cardiovascular events or other costly complications can strengthen the reimbursement argument and extend treatment duration.
FAQ addition: what is the most important long-term metric?
I would watch the combination of patient volume, persistence and net realized price. Together they determine the real economics of the obesity franchise.
